Refetoff et al. injected levothyroxine (LT4) via intra-amniotic installations into a fetus with MCT8 deficiency from GW 18 and continued LT4 treatment after birth [59]. This evidence concerns the gene SLC16A2 and hyperinsulinemic hypoglycemia, familial, 4.